Week of July 6th 2021 | Vol. 10, Issue 27
In This Issue
Featured Headlines
Recent Industry Transactions
Industry Trading Comps
Recent Industry Headlines
Market Reports
Upcoming Events

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory

Above is an overview of recent industry M&A activity. For additional information, see the charts below or click on the chart above to download complete transaction tables broken out by industry sub sectors.

For more information about our consumer healthcare JV with The Emerson Group, Daybreak Consumer Care, click here.
Recent Materials Providing Insight Into Healthcare Related Industries
Current M&A Pipeline
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics

Project Aspen
Sell-side | CDMO | Multinational CDMO headquartered in US

Project Athena
Sell-side / Licensing | Medical Device | Novel device for pelvic organ prolapse
Ritedose, owned by AGIC Capital and Humanwell Healthcare, recently hired William Blair to run an auction. While the process hasn’t launched, buyout firms are likely to bid for the pharma company, sourced told PE Hub.

Founded in 1995, Ritedose is a contract development manufacturer focusing on respiratory and ophthalmic products. The pharmaceutical company specializes n blow-fill-seal technology, where a container is formed, filled, and sealed in a continuous, highly automated process inside a sterile enclosed machine in a “clean room” facility.

AGIC, an Asian-European private equity firm, and Humanwell Healthcare, a China-based healthcare solutions provider, bought the business for $605 million in September 2017 from Olympus Partners.

An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
Pharma & Biotech
9 transactions totaling $176 million
Supplies, Equipment & Services
14 transactions totaling $3 million
Healthcare IT & Managed Care
6 transactions totaling $5 million
Healthcare Facilities & Distributors
7 transactions totaling $87 million
Pharma & Biotech
25 transactions totaling $1,602 million
Supplies, Equipment & Services
30 transactions totaling $2,597 million
Healthcare IT & Managed Care
11 transactions totaling $724 million
Healthcare Facilities & Distributors
2 transactions totaling $39 million
Pharma & Biotech
20 transactions totaling $2,248 million
Supplies, Equipment & Services
7 transactions totaling $403 million
Healthcare IT & Managed Care
1 transaction totaling $543 million
Healthcare Facilities & Distributors
1 transactions totaling $14 million
A Breakdown of Relevant Trading Multiples
Each week, we provide updated trading comps for leading companies from numerous healthcare sub-sectors.
To the right you will see a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
A Sampling of Relevant Industry Headlines from Last Week
Below are snippets from relevant industry news articles from the past week. For additional information or the article's complete text, click the headline link to view the original publication.
July 2, 2021 - Pharmaceutical Business Review
Philip Morris International has signed an agreement to acquire Fertin Pharma from private equity firm EQT for approximately $812.8m (DKK5.1bn). Denmark-based Fertin Pharma is a specialist contract development and manufacturing organisation in oral and intra-oral delivery technologies.

July 2, 2021 - Fierce Biotech
The rumors were true: Whispers grew this year that Parexel, owned for the past four years by Pamplona Capital, was seeking a sale or an IPO. Today, the whispers stopped as the CRO loudly declared it is being bought out for $8.5 billion. The suitors and soon-to-be owners are the Swedish investment firm EQT Private Equity and the U.S. giant Goldman Sachs Asset Management, giving Pamplona a healthy return on the $5 billion it spent on the CRO in 2017.

July 1, 2021 - Contract Pharma
Fujifilm Corporation is making and $850 million investment to the grow its core Bio CDMO subsidiary, Fujifilm Diosynth Biotechnologies, a biologics contract development and manufacturing organization (CDMO) with over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules and viral products expressed in a wide array of microbial, mammalian, and host/virus systems.

June 29, 2021 - Pharmaceutical Business Review
German generic drug manufacturer STADA Group has agreed to acquire a portfolio of well-established consumer healthcare brands from biopharmaceutical firm Sanofi to expand its European Consumer Healthcare portfolio. Under the terms of the deal, STADA will acquire 16 Consumer Healthcare products, which are commercialised in Europe. The products include Mitosyl, Silomat, Frubiase, Viscontour and Modafen, which are used for cold and flu, dry-cough, skin care and nutritional supplements.
Welcome to Bourne, let's talk.

Since our founding in 2001, Bourne Partners has remained focused on fulfilling the unique needs of established, middle-market healthcare and pharmaceutical companies across the globe. Our track record includes advising middle market companies in healthcare M&A assignments totaling more than $7 billion, and growing companies into successful and well-positioned pharmaceutical enterprises.